103 related articles for article (PubMed ID: 28476022)
21. Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.
Wu W; Schecker J; Würstle S; Schneider F; Schönfelder M; Schlegel J
Cancer Lett; 2018 Mar; 417():112-123. PubMed ID: 29306018
[TBL] [Abstract][Full Text] [Related]
22. Expression of the integrin coreceptor transglutaminase-2 in the RPE in vivo and in culture.
Ruggiero L; Finnemann SC
Adv Exp Med Biol; 2012; 723():709-15. PubMed ID: 22183397
[No Abstract] [Full Text] [Related]
23. ATP-binding cassette transporter 1 and transglutaminase 2 act on the same genetic pathway in the apoptotic cell clearance.
Iadevaia V; Rinaldi A; Falasca L; Pucillo LP; Alonzi T; Chimini G; Piacentini M
Cell Death Differ; 2006 Nov; 13(11):1998-2001. PubMed ID: 16691213
[No Abstract] [Full Text] [Related]
24. Disruption of KDM4C-ALDH1A3 feed-forward loop inhibits stemness, tumorigenesis and chemoresistance of gastric cancer stem cells.
Lang T; Xu J; Zhou L; Zhang Z; Ma X; Gu J; Liu J; Li Y; Ding D; Qiu J
Signal Transduct Target Ther; 2021 Sep; 6(1):336. PubMed ID: 34548470
[No Abstract] [Full Text] [Related]
25. FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.
Cheng P; Wang J; Waghmare I; Sartini S; Coviello V; Zhang Z; Kim SH; Mohyeldin A; Pavlyukov MS; Minata M; Valentim CL; Chhipa RR; Bhat KP; Dasgupta B; La Motta C; Kango-Singh M; Nakano I
Cancer Res; 2016 Dec; 76(24):7219-7230. PubMed ID: 27569208
[TBL] [Abstract][Full Text] [Related]
26. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
27. Gα(h)/transglutaminase-2 activity is required for maximal activation of adenylylcyclase 8 in human and rat glioma cells.
Obara Y; Yanagihata Y; Abe T; Dafik L; Ishii K; Nakahata N
Cell Signal; 2013 Mar; 25(3):589-97. PubMed ID: 23200849
[TBL] [Abstract][Full Text] [Related]
28. Transglutaminase 2: a new paradigm for NF-kappaB involvement in disease.
Kim SY
Adv Enzymol Relat Areas Mol Biol; 2011; 78():161-95. PubMed ID: 22220474
[No Abstract] [Full Text] [Related]
29. Transglutaminase 2 at the crossroads between cell death and survival.
Piacentini M; D'Eletto M; Falasca L; Farrace MG; Rodolfo C
Adv Enzymol Relat Areas Mol Biol; 2011; 78():197-246. PubMed ID: 22220475
[No Abstract] [Full Text] [Related]
30. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
31. Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling.
Yin J; Oh YT; Kim JY; Kim SS; Choi E; Kim TH; Hong JH; Chang N; Cho HJ; Sa JK; Kim JC; Kwon HJ; Park S; Lin W; Nakano I; Gwak HS; Yoo H; Lee SH; Lee J; Kim JH; Kim SY; Nam DH; Park MJ; Park JB
Cancer Res; 2017 Sep; 77(18):4973-4984. PubMed ID: 28754668
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
Meshram DD; Pike CVS; Coussons PJ
Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
[TBL] [Abstract][Full Text] [Related]
33. Tissue transglutaminase-induced down-regulation of matrix metalloproteinase-9.
Ahn JS; Kim MK; Hahn JH; Park JH; Park KH; Cho BR; Park SB; Kim DJ
Biochem Biophys Res Commun; 2008 Nov; 376(4):743-7. PubMed ID: 18809380
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1.
Coyle KM; Murphy JP; Vidovic D; Vaghar-Kashani A; Dean CA; Sultan M; Clements D; Wallace M; Thomas ML; Hundert A; Giacomantonio CA; Helyer L; Gujar SA; Lee PW; Weaver IC; Marcato P
Oncotarget; 2016 Jul; 7(28):44096-44112. PubMed ID: 27286452
[TBL] [Abstract][Full Text] [Related]
35. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
[TBL] [Abstract][Full Text] [Related]
36. The transglutaminase type 2 and pyruvate kinase isoenzyme M2 interplay in autophagy regulation.
Altuntas S; Rossin F; Marsella C; D'Eletto M; Diaz-Hidalgo L; Farrace MG; Campanella M; Antonioli M; Fimia GM; Piacentini M
Oncotarget; 2015 Dec; 6(42):44941-54. PubMed ID: 26702927
[TBL] [Abstract][Full Text] [Related]
37. IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
Oh K; Lee OY; Park Y; Seo MW; Lee DS
BMC Cancer; 2016 Sep; 16(1):724. PubMed ID: 27609180
[TBL] [Abstract][Full Text] [Related]
38. Physiopathological roles of human transglutaminase 2.
Gentile V
Adv Enzymol Relat Areas Mol Biol; 2011; 78():47-95. PubMed ID: 22220472
[No Abstract] [Full Text] [Related]
39. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
Kumar S; Donti TR; Agnihotri N; Mehta K
Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
[TBL] [Abstract][Full Text] [Related]
40. Metabolite profiling reveals a connection between aldehyde dehydrogenase 1A3 and GABA metabolism in breast cancer metastasis.
Dahn ML; Walsh HR; Dean CA; Giacomantonio MA; Fernando W; Murphy JP; Walker OL; Wasson MD; Gujar S; Pinto DM; Marcato P
Metabolomics; 2022 Jan; 18(1):9. PubMed ID: 34989902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
